BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma

Oncology & Biotech News
Published Online: Monday, July 25, 2011
Antoni Ribas, MD

Antoni Ribas, MD

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates (ORRs) and durable treatment responses in an open-label phase II study presented at ASCO 2011 by Antoni Ribas, MD, of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.

“A significant number of patients have ongoing responses between 10 and 12 months from the study start,” said Ribas. “Overall survival (OS) is 58% at 12 months. Median OS has not been reached.”

The study was initiated after the highly encouraging phase I results of the drug in 32 patients with a V600E activating mutation in the BRAF gene. In that study, vemurafenib led to a high incidence of tumor regression and an unconfirmed ORR of 81%. This high ORR has since been downgraded to a confirmed ORR of 53%.

The phase II BRIM-2 trial, which enrolled 132 previously treated patients, essentially validated the initial findings of high activity for the novel agent.

Table. Patient Baseline Disease Characteristics


Characteristic
No. (%)
N = 132
 
Stage at diagnosis
  M1a
  M1b
  M1c

33 (25)
18 (14)
81 (61)
 
Serum LDH
  Normal
  Elevated

67 (51)
65 (49)
 
No. prior therapies
  1
  2
  3

67 (51)
36 (27)
29 (22)
 
Previous ipilimumab or
tremelimumab
  No
  Yes


125 (95)
7 (5)
 

LDH indicates lactate dehydrogenase.
Adapted from Ribas et al. J Clin Oncol. 2011;29(suppl; abstr 8509).

Patients who had received at least 1 prior line of therapy for metastatic melanoma (49% had received 2 or more) received vemurafenib 960 mg PO BID until progression, unacceptable toxicity, or death. The primary endpoint was ORR by independent review.

At a median follow-up time of 10 months, the ORR was 53%, which met the study’s primary endpoint (a target ORR of 30% and lower boundary of 95% confidence interval of at least 20%). Stable disease was noted in 29% of patients, Ribas reported.

In the prespecified exploratory subset analysis, there were no differences in response rates according to age, gender, performance status, stage, number of prior therapies, or receipt of high-dose interleukin-2. Patients with high baseline lactate dehydrogenase (LDH) (>1.5 times upper limit of normal), however, were less likely to respond than those with normal LDH, he reported.

Median progression-free survival (PFS) was 6.7 months. OS was 77% at 6 months and 58% at 1 year. Median duration of response was 6.7 months, but responses are ongoing for as long as a year in many patients. Ribas added that time to response can also be delayed in some patients, even up to 1 year from start of therapy. At this time, 27% of patients are still on study.

The drug was well tolerated, with the most common side effects being arthralgias (58%), skin rash (52%), and photosensitivity (52%). He said that squamous cell carcinomas develop in about 25% of patients, tend to appear within the first 2 months, and are easily managed.

Dose modifications were necessary in 45% of patients; however, the median daily dose— 1750 mg—was 91% of the intended total dose. Only 4 patients discontinued due to drugrelated adverse events.

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer Congress®
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
More Reading
$auto_registration$